Aptose Biosciences, Inc. (APTO): Price and Financial Metrics


Aptose Biosciences, Inc. (APTO): $0.95

-0.01 (-0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add APTO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

APTO Stock Price Chart Interactive Chart >

Price chart for APTO

APTO Price/Volume Stats

Current price $0.95 52-week high $5.78
Prev. close $0.96 52-week low $0.90
Day low $0.92 Volume 201,200
Day high $0.98 Avg. volume 418,242
50-day MA $1.18 Dividend yield N/A
200-day MA $1.74 Market Cap 87.91M

Aptose Biosciences, Inc. (APTO) Company Bio


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company was founded in 1986 and is based in Mississauga, Canada.


APTO Latest News Stream


Event/Time News Detail
Loading, please wait...

APTO Latest Social Stream


Loading social stream, please wait...

View Full APTO Social Stream

Latest APTO News From Around the Web

Below are the latest news stories about Aptose Biosciences Inc that investors may wish to consider to help them evaluate APTO as an investment opportunity.

We Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | February 13, 2022

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

I’ve been bullish on Aptose Biosciences (APTO) for some time, but have also tried to make clear that I view this as an extremely risky play on potentially class-leading drugs for hematologic oncology. So far, that bullishness has not been rewarded at all, as disappointing clinical updates have led investors...

Stephen Simpson on Seeking Alpha | February 2, 2022

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Yahoo | December 31, 2021

Aptose to Participate in Two Biotech Events in January 2022

— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners Corporate Access Event. The Aptose management team will be hosting investor meetings during

Yahoo | December 29, 2021

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Read More 'APTO' Stories Here

APTO Price Returns

1-mo -18.10%
3-mo -21.49%
6-mo -58.33%
1-year -81.77%
3-year -52.74%
5-year -8.65%
YTD -29.63%
2021 -69.18%
2020 -22.75%
2019 196.86%
2018 -14.73%
2017 61.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.5132 seconds.